...
首页> 外文期刊>Journal of Cancer Research and Clinical Oncology >Repeated administration of short infusions of bendamustine: a phase I study in patients with advanced progressive solid tumours.
【24h】

Repeated administration of short infusions of bendamustine: a phase I study in patients with advanced progressive solid tumours.

机译:重复输注苯达莫司汀的短期输液:在晚期进行性实体瘤患者中进行的一项I期研究。

获取原文
获取原文并翻译 | 示例

摘要

PURPOSE: The cytotoxic agent bendamustine combines a purine-like benzimidazol and bifunctionally alkylating nitrogen mustard group. The drug has clinical antitumour activity in lymphoma, myeloma and breast cancer. In earlier dose-finding studies, the clinically tolerated dose for single-bolus bendamustine was 215 mg/m2; for fractionated therapy on 4 consecutive days it was 85 mg/m2. Anticholinergic symptoms, myelosuppression and cardiac dysrhythmia were dose-limiting. Our trial was designed to define the maximum tolerated dose of a short infusion schedule and to establish a recommended dose for ongoing and future clinical studies. METHODS: Patients with refractory malignant tumours qualified for the trial after written informed consent had been obtained. Bendamustine was given as a 30-min iv. infusion on days 1 and 8 of a 4 week cycle, with a starting dose of 100 mg/m2 and an increment per group of 20 mg/m2. RESULTS: Nineteen patients (13 male, 6 female; median age 57 years, range 37-74 years) were treated for one to two cycles with up to 180 mg/m2 bendamustine. At 160 mg/m2, fatigue grade 3 (NCI Common Toxicity Criteria) and dryness of the mouth grade 3 occurred in 2 patients, diarrhoea grade 3 in 1 patient; another patient with a history of myocardial infarction and arrhythmia developed a reversible total atrioventricular block after the first administration of 160 mg/m2 bendamustine. Other events, such as nausea/vomiting, loss of appetite, fever or chills, were not dose-limiting. Haematological toxicity was mild, except for sudden and long-lasting grade 3-4 lymphocytopenia, which occurred in all treatment cycles. Opportunistic infections were not observed. CONCLUSIONS: The maximum tolerated dose of a days-1 and -8 schedule of bendamustine, given as a 30-min i.v. infusion, is 160 mg/ m2; mouth dryness and fatigue are dose-limiting. The recommended dose for future trials is 140 mg/m2.
机译:目的:细胞毒剂苯达莫司汀将嘌呤样苯并咪唑和双功能烷基化氮芥子基团结合在一起。该药物在淋巴瘤,骨髓瘤和乳腺癌中具有临床抗肿瘤活性。在较早的剂量研究中,单次推注苯达莫司汀的临床耐受剂量为215 mg / m2;对于连续4天的分级治疗,为85 mg / m2。抗胆碱能症状,骨髓抑制和心律失常是剂量限制的。我们的试验旨在确定短期输注时间表的最大耐受剂量,并为正在进行的和未来的临床研究确定推荐剂量。方法:获得书面知情同意书后,具有难治性恶性肿瘤的患者有资格进行试验。静脉注射苯达莫司汀30分钟。在4周周期的第1天和第8天输注,起始剂量为100 mg / m2,每组的增量为20 mg / m2。结果:19例患者(男13例,女6例;中位年龄57岁,范围37-74岁)接受了高达180 mg / m2苯达莫司汀的一到两个周期的治疗。在160 mg / m2时,2例患者发生3级疲劳(NCI通用毒性标准)和口干3级,1例患者出现3级腹泻。初次服用160 mg / m2苯达莫司汀后,另一位有心肌梗塞和心律不齐病史的患者出现了可逆的总房室传导阻滞。其他事件(例如恶心/呕吐,食欲不振,发烧或发冷)不受剂量限制。血液学毒性轻微,但在所有治疗周期中均会发生突然且持续的3-4级淋巴细胞减少。没有观察到机会感染。结论:苯达莫司汀第1天和第8天的最大耐受剂量为静脉内30分钟。输液量为160 mg / m2;口腔干燥和疲劳是剂量限制的。未来试验的推荐剂量为140 mg / m2。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号